Company reports revenue growth of 69% and operating income of
$582,000 IRVINE, Calif., Aug. 14 /PRNewswire-FirstCall/ --
Cardiogenesis Corporation (Pink Sheets: CGCP), a leading developer
of surgical products used in the treatment of patients suffering
from severe angina, today reported financial results for its second
quarter ended June 30, 2008. Richard Lanigan, Cardiogenesis
President stated, "We are excited about our progress in year over
year quarterly revenue growth of 69%, and delivering solid
operating income. We believe this to be the result of progress in
executing on our new customer pipeline, as well as an increasing
interest in the utility of Transmyocardial Revascularization (TMR)
and our advanced platform on the part of clinicians. The positive
cash flow from operations will facilitate new initiatives for our
advanced delivery devices, the PEARL(R) 5.0 Robotic delivery system
and the PHOENIX combination delivery system." He continued, "The
FDA approved PEARL 5.0 is designed for use with surgical robots. In
the expanding role of minimally invasive cardiovascular surgery,
the PEARL 5.0 enables TMR treatment of patients with refractory
angina without the need for a sternotomy or thoracotomy. The
PHOENIX combines TMR with the precise injection of biologics. The
initial clinical results presented on the combination therapy of
TMR plus platelet rich plasma (PRP) and TMR plus stem cells is very
encouraging and, if proven, will expand the role for TMR. We
believe we have a significant opportunity today, as well as a
product pipeline to further expand the role for our proprietary
technology." Second Quarter Financial Results Sales in the second
quarter of 2008 totaled $4,119,000, a 69% increase from the prior
year second quarter sales of $2,436,000. The higher revenue in the
current year quarter is primarily attributable to a $1,350,000
increase in capital sales, and a $331,000, or 17%, increase in
disposable handpiece revenue as compared with the prior year
quarter. Of the $331,000 increase in handpiece revenue, $234,000
relates to revenue which had been previously deferred and became
recognizable during the quarter. Sales in the first six months of
2008 totaled $7,101,000, an increase of approximately 22% from
sales of $5,806,000 in the first six months of 2007. The year to
date increase as compared with the prior year period is primarily
attributable to a $1,246,000, or 127%, increase in capital sales
and a $71,000, or 2%, increase in disposable handpiece revenue. The
Company reported second quarter 2008 operating income of $582,000
as compared with an operating loss of $256,000 in the prior year
quarter. Net income for the quarter was $602,000, or $0.01 per
diluted share, as compared with a net loss of $255,000, or $0.01
per diluted share, in the 2007 second quarter. For the first six
months of 2008, Cardiogenesis reported operating income of $545,000
as compared with $209,000 for the same period in the prior year.
The net income for the first six months of 2008 was $566,000, or
$0.01 per diluted share, compared with $72,000, or $0.00 per
diluted share, for the first six months of 2007. Gross margin was
86% of sales for the quarter ended June 30, 2008 as compared with a
78% gross margin in the second quarter of 2007. Gross profit in
absolute dollars increased by $1,624,000 to $3,529,000 in the
current year quarter as compared with $1,905,000 for the 2007
second quarter. The increase in gross profit for the three month
period is primarily attributed to higher laser unit sales, an
increase in the average laser sales price, and recognition of
$234,000 of deferred revenue for which there is no associated cost
of goods sold. In addition, the cost of goods sold in the prior
year quarter included certain inventory impairment charges that did
not recur in the current year. For the six months ended June 30,
2008, gross margin was 84% of net revenues as compared to 80% of
net revenues for the six months ended June 30, 2007. Gross profit
in absolute dollars increased by $1,354,000 to $5,986,000 for the
six months ended June 30, 2008, as compared to $4,632,000 for the
six months ended June 30, 2007. The increase in gross profit for
the six month period is primarily attributed to an increase in the
average laser sales price as well as higher laser unit sales.
Research and development costs ("R&D") were $252,000 in the
second quarter of 2008 as compared with $297,000 in the 2007 second
quarter, a decrease of $45,000 or 15%. Year to date, R&D
expenses of $468,000 were $41,000 or 8% below the prior year period
of $509,000. Sales and marketing ("S&M") expenses of $1,795,000
in the quarter ended June 30, 2008 increased $833,000, or 87%,
compared with $962,000 for the quarter ended June 30, 2007. For the
six months ended June 30, 2008 S&M expenditures totaled
$3,322,000, an increase of $1,300,000, or 64%, compared with
$2,022,000 for the six months ended June 30, 2007. The increase in
S&M expenses for both the three- and six-month periods results
primarily from salary expenses, which increased $658,000 and
$915,000, respectively, over the corresponding prior year periods.
The salary expense increase resulted from higher capital sales
commissions related to the increase in capital sales, higher
commissions related to compensation programs for certain newly
hired sales personnel and salary expenses related to certain sales
management positions that were open in the corresponding prior year
period. In addition, travel expenses for the 2008 second quarter
and year to date periods increased over the prior year periods as a
result of higher costs and increased sales activity. General and
administrative expenditures ("G&A") for the quarter ended June
30, 2008 totaled $900,000 as compared to $902,000 during the
quarter ended June 30, 2007. For the six months ended June 30,
2008, G&A totaled $1,651,000 as compared to $1,892,000 for the
six months ended June 30, 2007. This represents a reduction of
$241,000, or 13%. About Cardiogenesis Corporation Cardiogenesis is
a medical device company specializing in the treatment of
cardiovascular disease and is a leader in devices that treat severe
angina. The Company's market leading holmium:YAG laser system and
single use fiber- optic delivery systems are used to perform a
FDA-cleared surgical procedure known as Transmyocardial
Revascularization (TMR). For more information on Cardiogenesis and
its products, please visit the Company's website at
http://www.cardiogenesis.com/ or the direct to patient website at
http://www.heartofnewlife.com/. Safe Harbor Statement With the
exception of historical information, the statements set forth above
include forward-looking statements. Any forward-looking statements
in this news release related to the possible effectiveness of the
Company's technologies and the effect of such technologies on the
Company's sales, profitability, the adoption of its technology and
products and FDA clearances are based on current expectations and
beliefs and are subject to numerous risks and uncertainties, many
of which are outside the Company's control, that could cause actual
results to differ materially. Factors that could affect the
accuracy of these forward-looking statements include, but are not
limited to: any inability by the Company to sustain profitable
operations or obtain additional financing on favorable terms if and
when needed; any failure to obtain required regulatory approvals;
failure of the medical community to expand its acceptance of TMR
procedures; possible adverse governmental rulings or regulations,
including any FDA regulations or rulings; the Company's ability to
comply with international and domestic regulatory requirements;
possible adverse Medicare or other third-party reimbursement
policies or adverse changes in those policies; any inability by the
Company to ship product on a timely basis; the Company's ability to
manage its growth; adverse economic developments that could
adversely affect the market for our products or our ability to
raise needed financing; actions by our competitors; and the
Company's ability to protect its intellectual property. Other
factors that could cause Cardiogenesis' actual results to differ
materially are discussed in the "Risk Factors" section of the
Company's Annual Report on Form 10-KSB for the year ended December
31, 2007 and the Company's other recent SEC filings. The Company
disclaims any obligation to update any forward-looking statements
as a result of developments occurring after the date of this press
release. CARDIOGENESIS CORPORATION CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS (in thousands, except per share amounts)
(unaudited) Three months ended Six months ended June 30, June 30,
2008 2007 2008 2007 Net revenues $4,119 $2,436 $7,101 $5,806 Cost
of revenues 590 531 1,115 1,174 Gross profit 3,529 1,905 5,986
4,632 Operating expenses: Research and development 252 297 468 509
Sales and marketing 1,795 962 3,322 2,022 General and
administrative 900 902 1,651 1,892 Total operating expenses 2,947
2,161 5,441 4,423 Operating income (loss) 582 (256) 545 209 Other
income (expense): Interest expense (1) (18) (21) (49) Interest
income 21 37 42 65 Non-cash interest expense - (30) - (76) Change
in fair value of derivatives - (76) - (190) Other non-cash income,
net - 88 - 113 Total other income (expense), net 20 1 21 (137) Net
income (loss) 602 $(255) 566 $72 Net earnings (loss) per share:
Basic $0.01 $(0.01) $0.01 $- Diluted $0.01 $(0.01) $0.01 $-
Weighted average shares outstanding: Basic 45,293 45,274 45,284
45,274 Diluted 45,306 45,274 45,313 45,274 CARDIOGENESIS
CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands)
June 30, December 31, 2008 2007 (unaudited) (audited) ASSETS
Current assets: Cash and cash equivalents $3,420 $2,824 Accounts
receivable, net of allowance for doubtful accounts of $28 1,664
1,763 Inventories 1,298 1,602 Prepaids and other current assets 385
486 Total current assets 6,767 6,675 Long-term investments in
marketable securities 150 - Property and equipment, net 428 457
Other assets, net 27 27 Total assets $7,372 $7,159 LIABILITIES AND
SHAREHOLDERS' EQUITY Current liabilities: Accounts payable $244
$169 Accrued liabilities 1,231 1,458 Deferred revenue 944 1,210
Current portion of capital lease obligation 9 12 Total current
liabilities 2,428 2,849 Capital lease obligation, less current
portion 16 19 Total liabilities 2,444 2,868 Commitments and
Contingencies Shareholders' equity: Preferred stock: no par value;
5,000 shares authorized; none issued and outstanding - - Common
stock: no par value; 75,000 shares authorized; 45,311 and 45,274
shares issued and outstanding, respectively 173,897 173,826
Accumulated deficit (168,969) (169,535) Total shareholders' equity
4,928 4,291 Total liabilities and shareholders' equity $7,372
$7,159 DATASOURCE: Cardiogenesis Corporation CONTACT: William R.
Abbott, Senior Vice President and Chief Financial Officer of
Cardiogenesis Corporation, +1-949-420-1800 Web site:
http://www.cardiogenesis.com/
Copyright